Chemical compound is basis for prostate cancer drug

Astellas Pharma Inc. of Japan and California's Medivation Inc. have announced a global agreement to develop and commercialize MDV3100, a chemical compound developed in UCLA science laboratories that is now Medivation's... [read full story]                    

powered by
Add Comment
There are also 2 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies